Latest Starpharma Holdings (SPHRF) Headlines Ne
Post# of 3
Posted On: 03/11/2014 10:54:31 AM
Latest Starpharma Holdings (SPHRF) Headlines
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
The Ellen's Corkrum Recordings and Its Legal Implication [opinion]
by Dashward A. Wumah - All Africa Global Media - Fri Dec 20, 6:34AM CST
In the wake of Ellen Corkrum, former head of the Liberia Airport Authority, and her fiance Melvin Johnson, secret recordings of Musa Bility former Chairman of the Board of Directors of the Liberia Airport Authority (LAA), along with others accused by the Government of Liberia for Economic Sabotage in the tune of over US$1 million. (All Africa 2013), the secret recordings of Defense Minister, Brownie Samukai, and Mr. Chris Massaquoi, the Inspector General of the Liberia National Police
Research Report: Viral Conjunctivitis - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8l93r/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Viral Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Viral Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Viral Conjunctivitis. - A review of the Viral Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Viral Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NanoViricides, Inc. NovaBay Pharmaceuticals, Inc. Starpharma Holdings Limited Foresight Biotherapeutics, Inc. Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/z8l93r/viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genital Herpes - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Genital Herpes
M2 - Tue Sep 03, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r3z3pp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Genital Herpes - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. Genital Herpes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Herpes pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AiCuris GmbH & Co. KG - Antigenics, Inc. - Flamel Technologies S.A. - Foamix Ltd. - NanoViricides, Inc. - Profectus BioSciences, Inc. - Starpharma Holdings Limited - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/r3...tal_herpes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration
PR Newswire - Wed Mar 13, 3:02AM CDT
Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) and Makhteshim Agan Group today announced a collaboration program. This will see Starpharma's Priostar® dendrimer technology applied to novel crop protection formulations across Makhteshim Agan's extensive product portfolio.
Herpes Simplex Virus Treatment - Global Strategic Business Report
M2 - Thu Feb 14, 6:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fnf3m/herpes_simplex) has announced the addition of the "Herpes Simplex Virus Treatment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Treatment Of Herpes Simplex Virus Infection 3. Hsv Vaccines - An Insight 4. Herpes Simplex Virus Infection - The Disease, Causes, Symptoms, And Diagnosis 5. Pipeline Analysis 6. Product Launche
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
The Ellen's Corkrum Recordings and Its Legal Implication [opinion]
by Dashward A. Wumah - All Africa Global Media - Fri Dec 20, 6:34AM CST
In the wake of Ellen Corkrum, former head of the Liberia Airport Authority, and her fiance Melvin Johnson, secret recordings of Musa Bility former Chairman of the Board of Directors of the Liberia Airport Authority (LAA), along with others accused by the Government of Liberia for Economic Sabotage in the tune of over US$1 million. (All Africa 2013), the secret recordings of Defense Minister, Brownie Samukai, and Mr. Chris Massaquoi, the Inspector General of the Liberia National Police
Research Report: Viral Conjunctivitis - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8l93r/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Viral Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Viral Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Viral Conjunctivitis. - A review of the Viral Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Viral Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NanoViricides, Inc. NovaBay Pharmaceuticals, Inc. Starpharma Holdings Limited Foresight Biotherapeutics, Inc. Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/z8l93r/viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Genital Herpes - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Genital Herpes
M2 - Tue Sep 03, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r3z3pp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Genital Herpes - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. Genital Herpes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Herpes pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AiCuris GmbH & Co. KG - Antigenics, Inc. - Flamel Technologies S.A. - Foamix Ltd. - NanoViricides, Inc. - Profectus BioSciences, Inc. - Starpharma Holdings Limited - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/r3...tal_herpes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration
PR Newswire - Wed Mar 13, 3:02AM CDT
Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) and Makhteshim Agan Group today announced a collaboration program. This will see Starpharma's Priostar® dendrimer technology applied to novel crop protection formulations across Makhteshim Agan's extensive product portfolio.
Herpes Simplex Virus Treatment - Global Strategic Business Report
M2 - Thu Feb 14, 6:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fnf3m/herpes_simplex) has announced the addition of the "Herpes Simplex Virus Treatment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Treatment Of Herpes Simplex Virus Infection 3. Hsv Vaccines - An Insight 4. Herpes Simplex Virus Infection - The Disease, Causes, Symptoms, And Diagnosis 5. Pipeline Analysis 6. Product Launche
(0)
(0)